

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **SB 282** SLS 18RS 697

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action: **w/ #2 HSE COMM AMD**

Proposed Amd.:

Sub. Bill For.:

Date: May 2, 2018	9:16 AM	Author: MILLS
Dept./Agy.: Insurance		Analyst: Willis Brewer
Subject: Provides relative to prescription drug pricing. (8/1/18)		

HEALTH/ACC INSURANCE RE2 NO IMPACT See Note
Provides relative to prescription drug pricing. (8/1/18)

Proposed law requires certain health insurance issuers to notify enrollees that they are subject to an excess consumer cost burden when they are charged more for a prescription drug than their insurer pays or would pay after considering drug rebates from the drug manufacturer into the total cost of the drug.

Proposed law requires certain health insurance issuers to certify to the commissioner of insurance that they passed on to the consumer at least 50% of the rebates received from drug manufacturers. Proposed law provides that in making this certification all information given to the commissioner shall be confidential.

Proposed law provides for enforcement against a health insurance issuer's license for failure to comply with proposed law, or providing a false certification. Proposed law exempts the Office of Group Benefits from the proposed law definition of "health insurance issuer."

EXPENDITURES	2018-19	2019-20	2020-21	2021-22	2022-23	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2018-19	2019-20	2020-21	2021-22	2022-23	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

Proposed legislation will have no impact to State or the Office of Group Benefits (OGB) expenditures since this measure excludes OGB as health insurance issuer that will have to provide to its enrollees at least 50% of the rebates it receives from prescription drugs.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S&H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S&H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Evan Brasseaux

Evan Brasseaux
Staff Director